Elevance Health, Inc. $ELV Shares Sold by Dana Investment Advisors Inc.

Dana Investment Advisors Inc. lowered its position in shares of Elevance Health, Inc. (NYSE:ELV) by 49.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 14,338 shares of the company’s stock after selling 14,047 shares during the period. Dana Investment Advisors Inc.’s holdings in Elevance Health were worth $4,633,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Legacy Financial Advisors Inc. increased its position in Elevance Health by 8.9% during the third quarter. Legacy Financial Advisors Inc. now owns 2,476 shares of the company’s stock worth $800,000 after buying an additional 203 shares during the period. Trajan Wealth LLC grew its position in shares of Elevance Health by 17.5% during the third quarter. Trajan Wealth LLC now owns 86,271 shares of the company’s stock worth $27,876,000 after acquiring an additional 12,846 shares during the last quarter. Equitable Trust Co. increased its holdings in shares of Elevance Health by 0.9% in the 3rd quarter. Equitable Trust Co. now owns 8,011 shares of the company’s stock valued at $2,589,000 after acquiring an additional 68 shares during the period. Vulcan Value Partners LLC raised its position in Elevance Health by 42.7% in the 3rd quarter. Vulcan Value Partners LLC now owns 419,195 shares of the company’s stock valued at $135,706,000 after purchasing an additional 125,464 shares during the last quarter. Finally, Vestmark Advisory Solutions Inc. boosted its stake in Elevance Health by 79.6% during the 3rd quarter. Vestmark Advisory Solutions Inc. now owns 3,371 shares of the company’s stock worth $1,089,000 after purchasing an additional 1,494 shares during the period. 89.24% of the stock is owned by institutional investors and hedge funds.

Elevance Health Stock Down 2.7%

ELV opened at $326.91 on Wednesday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.54 and a quick ratio of 1.54. Elevance Health, Inc. has a 12 month low of $273.71 and a 12 month high of $458.75. The stock has a market capitalization of $72.15 billion, a P/E ratio of 13.01, a P/E/G ratio of 1.86 and a beta of 0.50. The business has a 50 day simple moving average of $351.36 and a 200-day simple moving average of $335.31.

Elevance Health (NYSE:ELV) last announced its quarterly earnings data on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, topping analysts’ consensus estimates of $3.10 by $0.23. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The firm had revenue of $49.31 billion for the quarter, compared to analyst estimates of $49.52 billion. During the same quarter in the prior year, the company posted $3.84 earnings per share. Elevance Health’s quarterly revenue was up 9.6% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 25.500- EPS. On average, equities analysts anticipate that Elevance Health, Inc. will post 33.96 earnings per share for the current fiscal year.

Elevance Health Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th will be paid a $1.72 dividend. This represents a $6.88 annualized dividend and a dividend yield of 2.1%. This is a positive change from Elevance Health’s previous quarterly dividend of $1.71. The ex-dividend date is Tuesday, March 10th. Elevance Health’s dividend payout ratio (DPR) is 27.23%.

Analysts Set New Price Targets

ELV has been the topic of a number of recent research reports. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $332.00 price objective on shares of Elevance Health in a research note on Thursday, January 29th. Guggenheim dropped their price target on Elevance Health from $414.00 to $396.00 and set a “buy” rating on the stock in a research report on Thursday, January 29th. Mizuho set a $413.00 price objective on Elevance Health in a research report on Friday, January 9th. Wolfe Research set a $425.00 target price on Elevance Health and gave the company an “outperform” rating in a research note on Thursday, January 8th. Finally, Wall Street Zen cut Elevance Health from a “buy” rating to a “hold” rating in a research note on Sunday, February 8th. Twelve analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $390.55.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.